Magnetic control soft robot with electrical stimulation and drug release functions and preparation method

By designing a magnetically controlled soft robot, which utilizes a magnetic layer for positioning within the gastrointestinal tract and achieves precise drug release and electrical stimulation through a conductive hydrogel microneedle layer, the comprehensive problems in the treatment of gastrointestinal diseases in existing technologies are solved, providing a precise and safe treatment solution.

CN121314068APending Publication Date: 2026-01-13BEIHANG UNIV
View PDF 0 Cites 1 Cited by

Patent Information

Application Number
CN202511472345.1
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2025-10-15
Publication Date
2026-01-13

AI Technical Summary

Technical Problem

Existing treatments for gastrointestinal diseases suffer from problems such as inaccurate drug delivery, imprecise control of electrical stimulation, and limited energy supply, failing to meet the needs of comprehensive treatment.

Method used

A magnetically controlled soft robot with electrical stimulation and drug release functions is designed, comprising a magnetic layer, an electrical control layer, and a conductive hydrogel microneedle layer. It is driven by an external magnetic field to move and position itself in the gastrointestinal tract, and contacts the affected tissue through the conductive hydrogel microneedle layer to achieve precise drug release and electrical stimulation.

Benefits of technology

It achieves precise electrical stimulation and drug release for gastrointestinal diseases, providing comprehensive therapeutic effects, avoiding the shortcomings of traditional treatments, and improving the precision and safety of treatment.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN121314068A_ABST
    Figure CN121314068A_ABST
Patent Text Reader

Abstract

The invention discloses a magnetic control soft robot with electrical stimulation and drug release functions, and relates to the technical field of medical instruments. In the magnetic control soft robot provided by the invention, the magnetic layer is used for driving the body to move and position in the gastrointestinal tract under the driving of an external magnetic field; the electric control layer is used for supplying power and is responsible for controlling the opportunity and parameters of electric stimulation and controlling a drug release instruction; after a microneedle of the conductive hydrogel microneedle layer penetrates into tissue, nerve endings or muscle cells can be stimulated by applying a weak electric signal so as to regulate gastrointestinal motility, relieve pain and the like, a drug can be loaded in the microneedle, and when the electric signal is applied, the drug can be loaded in the microneedle by means of electromigration, electroosmosis and the like. Triggering the drug to be controllably released into the target tissue as required; the adhesive layer is used for temporarily anchoring the robot at a specific working position of the gastrointestinal tract; according to the magnetic control soft robot and the preparation method thereof, the comprehensive requirements of gastrointestinal tract disease treatment can be met.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] This invention relates to the field of medical device technology, and in particular to a magnetically controlled soft robot with electrical stimulation and drug release functions and its preparation method. Background Technology

[0002] Gastrointestinal diseases (such as gastroparesis, irritable bowel syndrome, and indigestion) affect a large population, and in severe cases can even lead to malnutrition and a decline in quality of life. Currently, the main treatments for gastrointestinal diseases include drug therapy, electrical stimulation therapy, and micromedical robots. However, these methods still face many challenges in clinical application. Traditional drug therapy (oral and intravenous injection) suffers from low bioavailability, unstable absorption, and significant side effects, making it difficult to accurately deliver drugs to local lesions. Electrical stimulation therapy requires invasive surgery to implant electrodes, increasing patient risks and discomfort. While micromedical robots can be used for drug delivery, they typically suffer from imprecise drug release control, lack of electrical stimulation functionality, and limited energy supply. Existing treatment methods generally cannot meet the comprehensive needs of gastrointestinal disease treatment. Summary of the Invention

[0003] The purpose of this invention is to provide a magnetically controlled soft robot with electrical stimulation and drug release functions and its preparation method, so as to solve the problems existing in the prior art and meet the comprehensive needs of gastrointestinal disease treatment.

[0004] To achieve the above objectives, the present invention provides the following solution: This invention provides a magnetically controlled soft robot with electrical stimulation and drug release functions, comprising a body for placement within the gastrointestinal tract. The body includes a magnetic layer, an electrical control layer, and a conductive hydrogel microneedle layer connected in sequence. The magnetic layer is used to move and position the body within the gastrointestinal tract under the drive of an external magnetic field. The conductive hydrogel microneedle layer carries a drug and is used to contact and penetrate the affected tissue. The electrical control layer is electrically connected to the conductive hydrogel microneedle layer and can energize the conductive hydrogel microneedle layer to release the drug to the affected tissue and provide electrical stimulation to the affected tissue.

[0005] Preferably, the body further includes an encapsulation layer disposed between the electronic control layer and the conductive hydrogel microneedle layer. The encapsulation layer is used to encapsulate the electronic control layer and enables the electronic control layer to be electrically connected to the conductive hydrogel microneedle layer.

[0006] Preferably, the conductive hydrogel microneedle layer includes a base layer and a plurality of drug-loaded microneedles. Each drug-loaded microneedle is provided with a drug release pore for releasing the drug. The drug-loaded microneedles are disposed on the side of the base layer opposite to the electrical control layer, and the base layer is electrically connected to the electrical control layer. The drug-loaded microneedles are used to penetrate the affected tissue, and the electrical control layer can energize the conductive hydrogel microneedle layer to enable the drug-loaded microneedles to release the drug and provide electrical stimulation to the affected tissue.

[0007] Preferably, the body further includes an adhesive layer, and the conductive hydrogel microneedle layers are arranged in two spaced-apart configurations. The adhesive layer is disposed on the encapsulation layer and positioned between the two conductive hydrogel microneedle layers. The adhesive layer is used to adhere to the affected tissue when the drug-loaded microneedles are inserted into the affected tissue.

[0008] Preferably, the electrical control layer can apply an electrical signal to the conductive hydrogel microneedle layer according to a preset program or a wireless command received from the outside, so as to control the drug release of the drug-loaded microneedles.

[0009] Preferably, the electrical control layer includes an insulating layer, a flexible receiving coil, and electronic devices. The flexible receiving coil and the electronic devices are disposed on the side of the insulating layer opposite to the magnetic layer. The insulating layer is connected to the magnetic layer. The encapsulation layer is connected to the insulating layer to cover the flexible receiving coil and the electronic devices. The flexible receiving coil is used to receive and acquire wireless energy. The electronic devices are electrically connected to the flexible receiving coil, and the lead electrodes of the electronic devices are electrically connected to the conductive hydrogel microneedle layer through pins. The electronic devices can receive and process the wireless energy acquired by the flexible receiving coil and apply voltage to the conductive hydrogel microneedle layer. The electronic devices can also communicate with the outside world and generate electrical signals according to external signals to drive the conductive hydrogel microneedle layer to release drugs to the affected tissue and provide electrical stimulation to the affected tissue.

[0010] Preferably, the body is made of a soft material, the body can be bent and placed inside the capsule, and the body can unfold after the capsule dissolves in the gastrointestinal tract.

[0011] The present invention also provides a method for preparing the above-mentioned magnetically controlled soft robot with electrical stimulation and drug release functions, comprising the following steps: Magnetic particles are dispersed in a polydimethylsiloxane prepolymer solution to obtain a magnetic composite slurry; the magnetic composite slurry is then cured to obtain a magnetic layer. Connect the magnetic layer and the electronic control layer; Gelatin methacryloyl group, conductive polymer, two-dimensional transition metal carbonitride, drug and water are mixed, and then a photoinitiator is added for further mixing. The mixture is then photocured on the side of the electrical control layer opposite to the magnetic layer to obtain a conductive hydrogel microneedle layer electrically connected to the electrical control layer. The magnetic layer, the electronic control layer, and the conductive hydrogel microneedle layer form the body.

[0012] Preferably, the electronic control layer includes an insulating layer, a flexible receiving coil, and electronic devices; nano-silver ink is deposited on the surface of the pretreated insulating layer and then sintered to form the flexible receiving coil, leads, and pins, thus obtaining a prefabricated electronic control layer; the prefabricated electronic control layer and the electronic devices are bonded together, so that the flexible receiving coil and the electronic devices are electrically connected through leads, and the lead electrodes of the electronic devices are electrically connected to the pins, thus obtaining the electronic control layer; Furthermore, during the preparation of the magnetic layer, the obtained magnetic composite slurry is coated or cast onto the side of the insulating layer away from the electronic device, and then cured to obtain the connector between the magnetic layer and the electronic control layer.

[0013] Preferably, the body further includes an encapsulation layer and an adhesive layer; After connecting the magnetic layer and the electronic control layer, the electronic control layer is encapsulated with polydimethoxysiloxane to obtain a pre-encapsulated layer; the surface of the pre-encapsulated layer is functionalized with acryloyl groups to obtain the encapsulated layer. Two spaced conductive hydrogel microneedle layers are prepared on the side of the encapsulation layer opposite to the electronic control layer; Acrylamide, crosslinking agent, thickener, buffer and water are mixed to obtain a precursor solution; the precursor solution is mixed with dopamine hydrochloride, and then mixed with a photoinitiator to obtain a prepolymer solution; The prepolymer solution is photocured on the surface of the encapsulation layer to obtain the adhesive layer; the adhesive layer is located on the surface of the encapsulation layer between the two conductive hydrogel microneedle layers.

[0014] The present invention achieves the following technical effects compared to the prior art: The present invention provides a magnetically controlled soft robot with electrical stimulation and drug release functions and its preparation method. During treatment, it is placed in the gastrointestinal tract orally. The magnetic layer drives the robot to move within the gastrointestinal tract and locate the affected tissue under the drive of an external magnetic field. It then contacts and penetrates the affected tissue through a conductive hydrogel microneedle layer. Since the conductive hydrogel microneedle layer carries the drug, and the electrical control layer is electrically connected to the conductive hydrogel microneedle layer, the electrical control layer can energize the conductive hydrogel microneedle layer to release the drug to the affected tissue and provide electrical stimulation to the affected tissue. This achieves the dual functions of precise electrical stimulation and drug release to the affected tissue, providing comprehensive treatment for gastrointestinal diseases. Attached Figure Description

[0015] To more clearly illustrate the technical solutions in the embodiments of the present invention or the prior art, the drawings used in the embodiments will be briefly introduced below. Obviously, the drawings described below are only some embodiments of the present invention. For those skilled in the art, other drawings can be obtained based on these drawings without creative effort.

[0016] Figure 1 This is a schematic diagram of the structure of the magnetically controlled soft robot provided in Embodiment 1 of the present invention; Figure 2 This is a schematic diagram of the communication connection of the electronic device provided in Embodiment 1 of the present invention; Figure 3 This is a schematic diagram illustrating the use of the magnetically controlled soft robot provided in Embodiment 1 of the present invention.

[0017] Figure 4 This is a schematic diagram of the manufacturing process of the magnetically controlled soft robot provided in Embodiment 2 of the present invention.

[0018] In the diagram: 1-body; 11-magnetic layer; 12-electronic control layer; 121-insulating layer; 122-flexible receiving coil; 123-electronic device; 1231-bridge rectifier; 1232-voltage regulator; 1233-boost converter module; 1234-microcontroller; 1236-power amplifier; 1235-wireless communication module; 124-pin; 13-conductive hydrogel microneedle layer; 131-base layer; 132-drug-loaded microneedle; 14-encapsulation layer; 141-conductive component; 15-adhesive layer; 2-capsule. Detailed Implementation

[0019] The technical solutions of the embodiments of the present invention will be clearly and completely described below with reference to the accompanying drawings. Obviously, the described embodiments are only some embodiments of the present invention, and not all embodiments. Based on the embodiments of the present invention, all other embodiments obtained by those skilled in the art without creative effort are within the scope of protection of the present invention.

[0020] The purpose of this invention is to provide a magnetically controlled soft robot with electrical stimulation and drug release functions and its preparation method, so as to solve the problems existing in the prior art and meet the comprehensive needs of gastrointestinal disease treatment.

[0021] To make the above-mentioned objects, features and advantages of the present invention more apparent and understandable, the present invention will be further described in detail below with reference to the accompanying drawings and specific embodiments.

[0022] Example 1 This embodiment provides a magnetically controlled soft robot with electrical stimulation and drug release functions. Please refer to [link / reference]. Figures 1-3 The device includes a body 1 for placement within the gastrointestinal tract. The body 1 comprises a magnetic layer 11, an electrical control layer 12, and a conductive hydrogel microneedle layer 13 connected in sequence. The magnetic layer 11 is used to move and position the body 1 within the gastrointestinal tract under the drive of an external magnetic field. The conductive hydrogel microneedle layer 13 contains a drug and is used to contact and penetrate the affected tissue. The electrical control layer 12 is electrically connected to the conductive hydrogel microneedle layer 13 and can energize the conductive hydrogel microneedle layer 13 to release the drug to the affected tissue and to electrically stimulate the affected tissue.

[0023] During treatment, the drug is administered orally into the gastrointestinal tract. Driven by an external magnetic field, the magnetic layer 11 moves the main body 1 within the gastrointestinal tract and positions it to the affected tissue. It then contacts and penetrates the affected tissue via the conductive hydrogel microneedle layer 13. Since the conductive hydrogel microneedle layer 13 carries the drug, and the electrical control layer 12 is electrically connected to it, the electrical control layer 12 can energize the conductive hydrogel microneedle layer 13 to release the drug to the affected tissue and provide electrical stimulation. This achieves the dual functions of precise electrical stimulation and drug release. Specifically, after the conductive hydrogel microneedle layer 13 penetrates the tissue, applying a weak electrical signal can stimulate nerve endings or muscle cells, thereby regulating gastrointestinal motility and relieving pain. The conductive hydrogel microneedle layer 13 can also carry the drug; when an electrical signal such as voltage is applied, the drug can be released on demand and in a controlled manner into the target tissue through electromigration and electroosmosis, providing comprehensive treatment for gastrointestinal diseases.

[0024] In an optional embodiment, more preferably, the body 1 further includes an encapsulation layer 14, which is disposed between the electronic control layer 12 and the conductive hydrogel microneedle layer 13. The encapsulation layer 14 is used to encapsulate the electronic control layer 12 and enables the electronic control layer 12 to be electrically connected to the conductive hydrogel microneedle layer 13.

[0025] The encapsulation layer 14 protects the electronic control layer 12, preventing direct contact between the internal circuits and devices and the external environment, which could affect the operation of the electronic control layer 12. Specifically, the encapsulation layer 14 has two conductive components 142. The electronic control layer 12 is electrically connected to two conductive hydrogel microneedle layers 13 through the two conductive components 141. The conductive components 141 are made of conductive adhesive, i.e., conductive epoxy resin, which conducts electricity and also enables the bonding and fixation of the electronic control layer 12 and the conductive hydrogel microneedle layer 13.

[0026] In an optional embodiment, more preferably, the conductive hydrogel microneedle layer 13 includes a base layer 131 and a plurality of drug-loaded microneedles 132. Each drug-loaded microneedle 132 is provided with a drug release pore for releasing drugs. The drug-loaded microneedles 132 are disposed on the side of the base layer 131 away from the electrical control layer 12. The base layer 131 is electrically connected to the electrical control layer 12. The drug-loaded microneedles 132 are used to pierce the affected tissue. The electrical control layer 12 can energize the conductive hydrogel microneedle layer 13 so that the drug-loaded microneedles 132 release drugs and provide electrical stimulation to the affected tissue.

[0027] The base layer 131 facilitates the distribution of multiple drug-loaded microneedles 132 arrays and the electrical connection between the electrical control layer 12 and the multiple drug-loaded microneedles 132, so as to apply electrical signals to release drugs and provide electrical stimulation.

[0028] In an optional embodiment, more preferably, the body 1 further includes an adhesive layer 15, and two conductive hydrogel microneedle layers 13 are arranged at intervals. The adhesive layer 15 is disposed on the encapsulation layer 14 and placed between the two conductive hydrogel microneedle layers 13. The adhesive layer 15 is used to adhere to the affected tissue when the drug-loaded microneedle 132 is inserted into the affected tissue.

[0029] The adhesive layer 15 enhances the robot's stability in the gastrointestinal tract, enabling precise electrical stimulation and drug release. Specifically, the adhesive layer 15 is made of polydopamine PDA hydrogel, which has good biocompatibility and flexibility, and can adhere to gastrointestinal tissue, effectively preventing the robot from deviating from its target position due to gastrointestinal peristalsis.

[0030] In an optional embodiment, more preferably, the electrical control layer 12 can apply an electrical signal to the conductive hydrogel microneedle layer 13 according to a preset program or a wireless command received from the outside, so as to control the drug release of the drug-loaded microneedles 132.

[0031] Among them, the conductive hydrogel microneedle layer 13 is made of conductive hydrogel material loaded with drugs. It transmits electrical stimulation signals through low-frequency current and acts on gastrointestinal tissues or mucosa to regulate gastrointestinal motility or other therapeutic effects. Since the drug-loaded microneedles 132 are loaded with drugs, these drug-loaded microneedles 132 can release drugs according to the electrical signals applied by the electrical control layer 12 through the principles of electroosmosis and electromigration.

[0032] In a preferred embodiment, the control layer 12 includes an insulating layer 121, a flexible receiving coil 122, and an electronic device 123. The flexible receiving coil 122 and the electronic device 123 are disposed on the side of the insulating layer 121 facing away from the magnetic layer 11. The insulating layer 121 is connected to the magnetic layer 11. The encapsulation layer 14 can be connected to the insulating layer 121 to cover the flexible receiving coil 122 and the electronic device 123. The flexible receiving coil 122 is used to receive inductively acquired wireless power, and the electronic device 123 is connected to the flexible receiving coil 122. Through lead wire electrical connection, both leads of electronic device 123 are electrically connected to the corresponding conductive component 141 via pin 124, and then electrically connected to the conductive hydrogel microneedle layer 13 via the conductive component 141. Electronic device 123 can receive and process the wireless energy acquired by flexible receiving coil 122 and apply voltage to conductive hydrogel microneedle layer 13. Electronic device 123 can also communicate with the outside world and generate electrical signals according to external signals to drive conductive hydrogel microneedle layer 13 to release drugs to the affected tissue and electrically stimulate the affected tissue.

[0033] The flexible receiving coil 122 is configured as a helical coil, transmitting high-frequency electromagnetic waves through an external transmitting coil. The flexible receiving coil 122 acquires wireless power through wireless induction. The electronic device 123 specifically includes a bridge rectifier 1231, a voltage regulator 1232, a microcontroller 1234, and a power amplifier 1236. The boost converter module 1233 is also electrically connected to the wireless communication module 1235 and the power amplifier 1236 to provide power. The external transmitting end transmits power to the flexible receiving coil 122 via high-frequency electromagnetic waves. After receiving the electromagnetic waves, the flexible receiving coil 122 converts them into alternating current (AC), which is then converted into direct current (DC) by the rectifier circuit of the bridge rectifier 1232. The voltage regulator 1232 adjusts the DC voltage to the required value through its internal voltage regulation circuit and supplies it to the microcontroller 1234. The boost converter module 1233 adjusts the DC voltage to the required value and supplies it to the power amplifier. 1236; The microcontroller 1234, such as an MCU, generates a PWM pulse width modulation signal based on the external control signal received by the wireless communication module 1235, such as a Bluetooth module, to control the electrical stimulation parameters. The PWM signal is transmitted to the power amplifier 1236, amplified, and then transmitted to the conductive hydrogel microneedle layer 13 through pin 124 and conductive component 141 for driving. The power amplifier 1236 is electrically connected to the two conductive components 141 through the pin 124 connecting the lead-out electrodes, and then electrically connected to the two conductive hydrogel microneedle layers 13. Specifically, the bridge rectifier 1231 adopts the BAS4002 model; the voltage regulator 1232 adopts the TLV70033 model; the boost converter module 1233 adopts the TPS63020 model; the microcontroller 1234 and the Bluetooth module are integrated using the nRF52832 model; and the power amplifier 1236 adopts the INA333 model.

[0034] In the optional embodiments of this example, it is more preferably that the body 1 is made of a soft material, the body 1 can be bent and placed inside the capsule 2, and the body 1 can unfold after the capsule 2 dissolves in the gastrointestinal tract.

[0035] In practical applications, to prevent damage to the main body 1 in non-affected areas, the main body 1 is bent and placed in a gelatin capsule 2. The capsule 2 is swallowed orally, and the gelatin capsule 2 dissolves in the intestines, releasing the folded main body 1. With the assistance of an external handheld magnet, the main body 1 is guided to the desired location in the stomach. The position of the handheld magnet is adjusted so that the conductive hydrogel microneedle layer 13 penetrates the gastrointestinal mucosa and contacts the tissue. Programmable electrical pulses are transmitted through near-field inductive coupling, or drugs are released or electrical stimulation is performed through the conductive hydrogel microneedle layer 13. After completing the task, the main body 1 can be excreted from the body under the guidance of the handheld magnet.

[0036] In addition, to prevent damage to the electronic components 123 during the bending process of the main body 1, the modules of the electronic components 123 can be separated to avoid mutual compression after bending.

[0037] Example 2 This embodiment provides a method for fabricating a magnetically controlled soft robot with electrical stimulation and drug release functions as described in Embodiment 1, comprising the following steps: Magnetic particles are dispersed in a polydimethylsiloxane (PDMS) prepolymer solution to obtain a magnetic composite slurry; the magnetic composite slurry is cured to obtain a magnetic layer 11; the magnetic layer 11 and the electrostatic control layer 12 are connected; gelatin methacryloyl (GelMA), conductive polymer, two-dimensional transition metal carbonitride, drug and water are mixed, and a photoinitiator is added for further mixing; the electrostatic control layer 12 is photocured on the side opposite to the magnetic layer 11 to obtain a conductive hydrogel microneedle layer 13 electrically connected to the electrostatic control layer 12; the magnetic layer 11, the electrostatic control layer 12 and the conductive hydrogel microneedle layer 13 form the body 1.

[0038] In this embodiment, the magnetic particles may include neodymium iron boron (NdFeB) magnetic particles; the polydimethylsiloxane prepolymer solution may include polydimethylsiloxane prepolymer and a crosslinking agent. In this embodiment, the mass ratio of magnetic particles to polydimethylsiloxane prepolymer solution may be 0.3~0.6:1, specifically 0.3:1, 0.4:1, 0.5:1, or 0.6:1. In this embodiment, the curing temperature may be 80~120℃, specifically 80℃, 90℃, 100℃, 110℃, or 120℃; the curing time may be 0.5~1h, specifically 0.5h, 0.6h, 0.7h, 0.8h, 0.9h, or 1h. In this embodiment, the thickness of the magnetic layer may be 0.5mm. In this embodiment, before the magnetic composite slurry is cured, it may further include magnetically assisted orientation of the magnetic composite slurry. By magnetically assisted orientation of the magnetic composite slurry, the prepared magnetic layer can achieve anisotropic magnetic response, thereby improving the flexibility of control. And by controlling the thickness of the magnetic layer, the overall size of the magnetically controlled soft robot is avoided from being too large.

[0039] More preferably, the electronic control layer 12 includes an insulating layer 121, a flexible receiving coil 122, and an electronic device 123; nano-silver ink is deposited on the surface of the pretreated insulating layer 121 and then sintered to form the flexible receiving coil 122, leads, and pins 124, thus obtaining a prefabricated electronic control layer; the prefabricated electronic control layer and the electronic device 123 are bonded together so that the flexible receiving coil 122 and the electronic device 123 are electrically connected through leads, and the lead-out electrodes of the electronic device 123 are electrically connected to the pins 124, thus obtaining the electronic control layer 12; and during the preparation of the magnetic layer 11, the obtained magnetic composite slurry is coated or poured onto the side of the insulating layer 121 away from the electronic device 123, and then cured to obtain the connector of the magnetic layer 11 and the electronic control layer 12.

[0040] In this embodiment, the deposition of nano-silver ink may include aerosol-assisted 3D printing (AJP); the printing method of aerosol-assisted 3D printing may include high-resolution inkjet printing. In this embodiment, sintering may include laser local high-temperature sintering; the temperature of laser local high-temperature sintering may be 150~220℃, specifically 150℃, 170℃, 190℃, 200℃ or 220℃. In this embodiment, the adhesive used for bonding may include conductive silver paste; the coating method of the adhesive may include dot coating. In this embodiment, the material of the insulating layer 121 may include polyimide.

[0041] More preferably, the body 1 further includes an encapsulation layer 14; after connecting the magnetic layer 11 and the electronic control layer 12, the electronic control layer 12 is encapsulated with polydimethoxysiloxane to obtain a pre-encapsulation layer; the surface of the pre-encapsulation layer is subjected to acryloyl functionalization treatment to obtain the encapsulation layer 14.

[0042] The encapsulation step may include: mixing a polydimethoxysiloxane prepolymer and a crosslinking agent, and performing a first curing on the surface of the electrical control layer 12; performing a second curing on the surface of the electrical control layer 12 with conductive silver epoxy resin adhesive, so that the conductive silver epoxy resin adhesive connects and leads out two pins 124, thus obtaining a pre-encapsulated layer. In this embodiment, the mass ratio of the polydimethoxysiloxane prepolymer to the crosslinking agent can be 10:~20:1, specifically 10:1, 12:1, 15:1, 16:1, 18:1 or 20:1; the first curing temperature can be 60~80℃, specifically 60℃, 65℃, 70℃, 75℃ or 80℃, and the time can be 1~2h, specifically 1h, 1.2h, 1.4h, 1.6h, 1.8h or 2h. In this embodiment, the conductive silver epoxy resin adhesive can specifically be an EPO-TEKH20E two-component silver-filled conductive epoxy resin adhesive; the second curing temperature can be 80~90℃, specifically 80℃, 82℃, 84℃, 86℃, 88℃ or 90℃, and the time can be 1~2h, specifically 1h, 1.2h, 1.4h, 1.6h, 1.8h or 2h. In this embodiment, the silver electrode pins are connected to the conductive hydrogel microneedle layer 13 by the conductive silver epoxy resin adhesive, realizing the export of electrical signals. The electronic control layer 12 is encapsulated by polydimethoxysiloxane, providing mechanical protection and environmental isolation for the electronic devices in the electronic control layer 12.

[0043] The acryloyl functionalization step may include: subjecting the pre-encapsulated layer to surface oxygen plasma treatment (O2 plasma), and then thermally condensing the treated surface in an aqueous alcoholic solution of 3-(trimethoxysilyl)propyl methacrylate (TMSPMA) to obtain the encapsulation layer 14. In this embodiment, the power of the surface oxygen plasma treatment can be 60~90W, specifically 60W, 65W, 70W, 75W, 80W, 85W, or 90W, and the time can be 45~90s, specifically 45s, 50s, 60s, 70s, 80s, or 90s. In this embodiment, the volume concentration of 3-(trimethoxysilyl)propyl methacrylate in the ethanol-water solution of 3-propyl methacrylate can be 1-1.5%, specifically 1%, 1.1%, 1.2%, 1.3%, 1.4%, or 1.5%; the volume concentration of water can be 1-2%, specifically 1%, 1.2%, 1.4%, 1.6%, 1.8%, or 2%; the acrylation reaction temperature can be room temperature, and the time can be 30-45 min, specifically 30 min, 35 min, 37 min, 40 min, 42 min, or 45 min. In this embodiment, after completing the acrylation reaction, the surface of the obtained acrylated encapsulation layer may be subjected to alcohol washing followed by nitrogen blowing; the alcohol used for alcohol washing can specifically be anhydrous ethanol. In this embodiment, the heat condensation temperature is 80~90℃, specifically 80℃, 82℃, 84℃, 86℃, 88℃, or 90℃, and the time is 10~20min, specifically 10min, 12min, 14min, 16min, 18min, or 20min. This embodiment promotes silane condensation through heat condensation. By performing acryloyl functionalization treatment on the surface of the pre-encapsulation layer, a 3-(trimethoxysilyl)propyl methacrylate layer is formed on the surface of the pre-encapsulation layer. This layer can form covalent bonds with the conductive hydrogel microneedle layer 13 and the adhesive layer 15, improving interfacial adhesion and achieving a stable connection.

[0044] More preferably, the body 1 further includes two spaced conductive hydrogel microneedle layers 13 prepared on the side of the encapsulation layer 14 opposite to the electronic control layer 12. In this embodiment, the preparation method of the conductive hydrogel microneedle layer 13 may include: first mixing gelatin methacryloyl groups and water to obtain a mixed solution; second mixing the mixed solution, a conductive polymer dispersion, and a two-dimensional transition metal carbonitride dispersion to obtain a mixed slurry; third mixing the mixed slurry, a photoinitiator, and a drug, and then performing photocuring via a mask to obtain the conductive hydrogel microneedle layer 13.

[0045] In this embodiment, the water used for the first mixing can be deionized water; the water temperature can be 60°C; there are no special limitations on the method of the first mixing, as long as the gelatin methacryloyl groups are completely dissolved in the water, specifically magnetic stirring. In this embodiment, the concentration of gelatin methacryloyl groups in the mixed solution can be 5~10% w / v, specifically 5% w / v, 6% w / v, 7% w / v, 8% w / v, 9% w / v, or 10% w / v.

[0046] The conductive polymer in the conductive polymer dispersion can be poly(3,4-ethylenedioxythiophene)-poly(styrene sulfonate) (PEDOT:PSS); the mass percentage of the conductive polymer dispersion to the volume of the mixed solution can be 0.3%~0.7%w / v, specifically 0.3%w / v, 0.4%w / v, 0.5%w / v, 0.6%w / v, or 0.7%w / v; the two-dimensional transition metal carbonitride in the two-dimensional transition metal carbonitride dispersion can be MXene; the mass percentage of the two-dimensional transition metal carbonitride dispersion to the volume of the mixed solution can be 0.05~0.2%w / v, specifically 0.05%w / v, 0.1%w / v, 0.12%w / v, 0.15%w / v, or 0.2%w / v; there is no particular limitation on the second mixing method, and conventional mixing methods in the art can be used, specifically vortex oscillation. In this embodiment, the drug loading process of the target drug is completed by directly dissolving the drug in the mixed slurry.

[0047] The photoinitiator can be lithium phenyl-2,4,6-trimethylbenzoylphosphinate (LAP); the mass percentage of the photoinitiator to the volume of the mixed slurry can be 0.5 w / v%. The third mixture can be a light-protected mixture; the drug can be an anti-inflammatory drug and / or an antibiotic.

[0048] The photocuring step can be specifically as follows: pour the precursor liquid obtained from the third mixture into the mold, remove air bubbles, heat and concentrate, and then continue to pour in the precursor liquid; repeat the process of heating and concentrating and pouring in the precursor liquid until the precursor liquid in the mold reaches a viscous state; align the surface of the encapsulation layer 14 with the mold containing the precursor liquid, cover it with a photomask and then cure it with ultraviolet light, separate the mold, and obtain the conductive hydrogel microneedle layer 13.

[0049] Among them, the degassing method can be centrifugation; the heating concentration temperature can be 30~35℃, specifically 30℃, 31℃, 32℃, 33℃, 34℃ or 35℃, and the initial heating concentration time can be 6~12h, specifically 6h, 7h, 8h, 9h, 10h, 11h or 12h; the wavelength of the ultraviolet light used for ultraviolet curing can be 405nm, and the ultraviolet curing time can be 10~30s, specifically 10s, 15s, 20s, 25s or 30s.

[0050] More preferably, the body 1 further includes an adhesive layer 15. Acrylamide (AAm), a crosslinking agent, a thickener, a buffer, and water are mixed to obtain a precursor solution; the precursor solution is mixed with dopamine hydrochloride, and then mixed with a photoinitiator to obtain a prepolymer solution; the prepolymer solution is photocured on the surface of the encapsulation layer 14 to obtain the adhesive layer 15; the adhesive layer 15 is located on the surface of the encapsulation layer 14 between the two conductive hydrogel microneedle layers 13.

[0051] The crosslinking agent can be polyethylene glycol diacrylate (PEGDA), the thickener can be sodium alginate (SA), and the buffer can be triethanolamine (TEA). Mixing may include dissolving acrylamide, the crosslinking agent, and the thickener in an aqueous buffer solution. The mass percentage of acrylamide in the aqueous buffer solution can be 10-12% w / v, specifically 10%, 10.5%, 11%, 11.5%, or 12% w / v; the mass percentage of the crosslinking agent in the aqueous buffer solution can be 0.1-0.15%. The w / v ratio can be specifically 0.1% w / v, 0.11% w / v, 0.12% w / v, 0.13% w / v, 0.14% w / v, or 0.15% w / v; the percentage of the thickener's mass in the buffer aqueous solution can be 2-4% w / v, specifically 2% w / v, 2.5% w / v, 3% w / v, 3.5% w / v, or 4% w / v; the concentration of the buffer in the buffer aqueous solution can be 0.2 mol / L (0.2 M); the percentage of dopamine hydrochloride's mass in the precursor solution can be 0.035-0.048%. The w / v%, specifically 0.035% w / v, 0.038% w / v, 0.04% w / v, 0.045% w / v, or 0.048% w / v; the photoinitiator can be lithium phenyl-2,4,6-trimethylbenzoylphosphine; the percentage of the mass of the photoinitiator relative to the volume of the dopamine hydrochloride-precursor solution obtained by mixing the precursor solution and dopamine hydrochloride can be 0.5 w / v.

[0052] The mixing time for the dopamine hydrochloride precursor solution and photoinitiator can be 30-40 min, specifically 30 min, 32 min, 34 min, 36 min, 38 min, or 40 min. The photocuring step can be specifically as follows: the prepolymer solution is dropped onto the surface of the encapsulation layer 14 located between the two conductive hydrogel microneedle layers 13, covered with a photomask, and then cured with ultraviolet light, followed by cleaning to obtain the adhesion layer 15. The wavelength of the ultraviolet light used for ultraviolet curing can be 405 nm, and the curing time can be 10-30 s, specifically 10 s, 15 s, 20 s, 25 s, or 30 s. Cleaning can be specifically performed using deionized water.

[0053] The detailed fabrication method of the magnetically controlled soft robot with electrical stimulation and drug release functions is as follows: Preparation of magnetic layer 11: Neodymium iron boron magnetic particles are dispersed in a polydimethylsiloxane prepolymer solution to obtain a magnetic composite slurry; the magnetic composite slurry is then cured to obtain magnetic layer 11. The mass ratio of magnetic particles to polydimethylsiloxane prepolymer solution is 0.5:1. After obtaining the magnetic composite slurry, it is coated onto the polyimide insulating layer 121 using a doctor blade coating method, with a coating thickness of 0.5 mm. The magnetic composite slurry is then oriented with magnetic field assistance and cured at 80℃ for 1 hour to obtain magnetic layer 11.

[0054] Preparation of the electrical control layer 12: Nano-silver ink is deposited on the surface of the pretreated insulating layer 121 on the side opposite to the magnetic layer 11, and then laser local high-temperature sintering is performed to form a flexible silver coil (i.e., flexible receiving coil 122), leads and pins 124, thus obtaining the pre-fabricated electrical control layer. The sintering temperature is 200℃. Conductive silver paste is used to dot-coat and bond the pre-fabricated electrical control layer and the electronic device 123, so that the flexible silver coil and the electronic device 123 form an electrical connection, thus obtaining the electrical control layer 12, and further obtaining the connector between the magnetic layer 11 and the electrical control layer 12.

[0055] Preparation of encapsulation layer 14: Polydimethoxysiloxane prepolymer and crosslinking agent 15:1 were mixed and cured on the surface of electrical control layer 12 at 80°C for 1 hour; then conductive silver epoxy resin adhesive was applied to the surface of the pins 124 of the two lead electrodes to electrically connect the conductive silver epoxy resin adhesive to the pins 124, and cured at 80°C for 1 hour to obtain the pre-encapsulation layer. The surface of the obtained pre-encapsulation layer was subjected to oxygen plasma treatment (power 60W, treatment time 45s), and then the treated surface was immersed in 3-(trimethoxysilyl)propyl methacrylate (TMSPMA) ethanol solution (containing 1% deionized water) and acrylamide reaction was carried out at room temperature for 45 minutes, wherein the volume concentration of 3-(trimethoxysilyl)propyl methacrylate in the TMSPMA ethanol solution was 1%; the volume concentration of water was 1%. After the acrylation reaction is completed, the surface of the acrylated encapsulation layer is rinsed with anhydrous ethanol, dried with nitrogen, and then baked at 80°C for 10 min for thermal condensation to obtain encapsulation layer 14.

[0056] Preparation of conductive hydrogel microneedle layer 13: Gelatin methacryloyl powder was dissolved in deionized water at 60℃ and stirred magnetically until completely dissolved to obtain a mixed solution. The concentration of gelatin methacryloyl in the mixed solution was 10% w / v. PEDOT:PSS dispersion and MXene dispersion were added sequentially to the obtained mixed solution and vortexed to mix, resulting in a mixed slurry. The mass percentage of PEDOT:PSS dispersion to the volume of the mixed solution was 0.4% w / v, and the mass percentage of MXene dispersion to the volume of the mixed solution was 0.1% w / v. Subsequently, a photoinitiator LAP with a mass-volume concentration of 0.25% w / v was added to the obtained mixed slurry. The mixture was stirred continuously under light-protected conditions until the LAP was completely dissolved, resulting in a homogeneous precursor solution. Specific drugs were selected according to actual needs and added to the precursor solution. The resulting precursor solution was then poured into a microneedle mold, centrifuged to remove air bubbles, and then concentrated at 30°C for 6 hours. The process of filling the mold with the precursor solution was repeated until the precursor solution in the mold reached a viscous state. The surface of the encapsulation layer 14 was aligned with the mold containing the hydrogel. A photomask was then used to cover the mold, and UV curing-induced polymerization was performed by irradiation with 405nm ultraviolet light for 30 seconds. After photocuring, the mold was separated to obtain the conductive hydrogel microneedle layer 13.

[0057] Preparation of adhesive layer 15: Acrylamide, polyethylene glycol diacrylate and sodium alginate were dissolved in a 0.2M triethanolamine aqueous solution to obtain a precursor solution, wherein the concentration of acrylamide was 12% w / v; the concentration of polyethylene glycol diacrylate was 0.1% w / v; and the concentration of sodium alginate was 2% w / v.

[0058] Dopamine hydrochloride was added to the obtained precursor solution and magnetically stirred until completely dissolved. Initiator LAP was then added to the resulting solution (dopamine hydrochloride concentration 0.048 w / v%) and stirred for 30 min to obtain a prepolymer solution with a LAP concentration of 0.5 w / v%. The obtained prepolymer solution was then dropped onto the surface of the encapsulation layer 14 located between the two conductive hydrogel microneedle layers 13, covered with a photomask, and irradiated with 405 nm ultraviolet light for 30 s for UV-curing induced polymerization. After UV curing, the mixture was washed with deionized water to obtain the adhesion layer 15, thus obtaining the bulk 1.

[0059] Specific examples have been used to illustrate the principles and implementation methods of this invention. The descriptions of the above embodiments are only for the purpose of helping to understand the method and core ideas of this invention. Furthermore, those skilled in the art will recognize that, based on the ideas of this invention, there will be changes in the specific implementation methods and application scope. Therefore, the content of this specification should not be construed as a limitation of this invention.

Claims

1. A magnetically controlled soft robot with electrical stimulation and drug release functions, characterized in that: Includes a body (1) for placement in the gastrointestinal tract, the body (1) comprising a magnetic layer (11), an electro-control layer (12) and a conductive hydrogel microneedle layer (13) connected in sequence. The magnetic layer (11) is used to drive the body (1) to move and position in the gastrointestinal tract under the drive of an external magnetic field; the conductive hydrogel microneedle layer (13) contains drugs and is used to contact and penetrate the affected tissue; the electrical control layer (12) is electrically connected to the conductive hydrogel microneedle layer (13) and can energize the conductive hydrogel microneedle layer (13) to release drugs to the affected tissue and to electrically stimulate the affected tissue.

2. The magnetically controlled soft robot with electrical stimulation and drug release functions according to claim 1, characterized in that: The body (1) further includes an encapsulation layer (14), which is disposed between the electronic control layer (12) and the conductive hydrogel microneedle layer (13). The encapsulation layer (14) is used to encapsulate the electronic control layer (12) and enables the electronic control layer (12) to be electrically connected to the conductive hydrogel microneedle layer (13).

3. The magnetically controlled soft robot with electrical stimulation and drug release functions according to claim 2, characterized in that: The conductive hydrogel microneedle layer (13) includes a base layer (131) and a plurality of drug-loaded microneedles (132). Each drug-loaded microneedle (132) is provided with a drug release pore for releasing drugs. The drug-loaded microneedles (132) are disposed on the side of the base layer (131) away from the electrical control layer (12). The base layer (131) is electrically connected to the electrical control layer (12). The drug-loaded microneedles (132) are used to pierce the affected tissue. The electrical control layer (12) can energize the conductive hydrogel microneedle layer (13) so that the drug-loaded microneedles (132) release drugs and provide electrical stimulation to the affected tissue.

4. The magnetically controlled soft robot with electrical stimulation and drug release functions according to claim 3, characterized in that: The body (1) further includes an adhesive layer (15), and the conductive hydrogel microneedle layers (13) are arranged in two spaced-apart configurations. The adhesive layer (15) is disposed on the encapsulation layer (14) and placed between the two conductive hydrogel microneedle layers (13). The adhesive layer (15) is used to adhere to the affected tissue when the drug-loaded microneedle (132) is inserted into the affected tissue.

5. The magnetically controlled soft robot with electrical stimulation and drug release functions according to claim 4, characterized in that: The electrical control layer (12) can apply an electrical signal to the conductive hydrogel microneedle layer (13) according to a preset program or a wireless command received from the outside, so as to control the drug release of the drug-loaded microneedles (132).

6. The magnetically controlled soft robot with electrical stimulation and drug release functions according to claim 2, characterized in that: The electronic control layer (12) includes an insulating layer (121), a flexible receiving coil (122), and an electronic device (123). The flexible receiving coil (122) and the electronic device (123) are disposed on the side of the insulating layer (121) facing away from the magnetic layer (11). The insulating layer (121) is connected to the magnetic layer (11). The encapsulation layer (14) can be connected to the insulating layer (121) to cover the flexible receiving coil (122) and the electronic device (123). The flexible receiving coil (122) is used to receive inductively acquired wireless power. The device (123) is electrically connected to the flexible receiving coil (122), and the lead-out electrode of the electronic device (123) is electrically connected to the conductive hydrogel microneedle layer (13) through the pin (124). The electronic device (123) can receive and process the wireless energy acquired by the flexible receiving coil (122) and apply voltage to the conductive hydrogel microneedle layer (13). The electronic device (123) can also communicate with the outside world and generate electrical signals according to external signals to drive the conductive hydrogel microneedle layer (13) to release drugs to the affected tissue and electrically stimulate the affected tissue.

7. The magnetically controlled soft robot with electrical stimulation and drug release functions according to any one of claims 1-6, characterized in that: The body (1) is made of soft material. The body (1) can be bent and placed inside the capsule (2). The body (1) can be unfolded after the capsule (2) dissolves in the gastrointestinal tract.

8. A method for preparing the magnetically controlled soft robot with electrical stimulation and drug release functions as described in any one of claims 1-7, characterized in that, Includes the following steps: Magnetic particles are dispersed in a polydimethylsiloxane prepolymer solution to obtain a magnetic composite slurry; the magnetic composite slurry is then cured to obtain a magnetic layer (11). Connect the magnetic layer (11) and the electronic control layer (12); Gelatin methacryloyl group, conductive polymer, two-dimensional transition metal carbonitride, drug and water are mixed, and then a photoinitiator is added for mixing. The mixture is then photocured on the side of the electrical control layer (12) away from the magnetic layer (11) to obtain a conductive hydrogel microneedle layer (13) electrically connected to the electrical control layer (12). The magnetic layer (11), the electro-control layer (12), and the conductive hydrogel microneedle layer (13) form the body (1).

9. The preparation method according to claim 8, characterized in that: The electronic control layer (12) includes an insulating layer (121), a flexible receiving coil (122), and an electronic device (123). Nano-silver ink is deposited on the surface of the pretreated insulating layer (121) and then sintered to form the flexible receiving coil (122), leads, and pins (124) to obtain a prefabricated electronic control layer. The prefabricated electronic control layer and the electronic device (123) are bonded together so that the flexible receiving coil (122) and the electronic device (123) are electrically connected through the leads, and the lead-out electrodes of the electronic device (123) are electrically connected to the pins (124) to obtain the electronic control layer (12). Furthermore, during the preparation of the magnetic layer (11), the obtained magnetic composite slurry is coated or cast onto the side of the insulating layer (121) away from the electronic device (123), and then cured to obtain the connector of the magnetic layer (11) and the electronic control layer (12).

10. The preparation method according to claim 9, characterized in that: The body (1) also includes an encapsulation layer (14) and an adhesive layer (15). After connecting the magnetic layer (11) and the electrical control layer (12), the electrical control layer (12) is encapsulated with polydimethoxysiloxane to obtain a pre-encapsulated layer; the surface of the pre-encapsulated layer is subjected to acryloyl functionalization treatment to obtain the encapsulated layer (14). Two spaced conductive hydrogel microneedle layers (13) are prepared on the side of the encapsulation layer (14) away from the electrical control layer (12). Acrylamide, crosslinking agent, thickener, buffer and water are mixed to obtain a precursor solution; the precursor solution is mixed with dopamine hydrochloride, and then mixed with a photoinitiator to obtain a prepolymer solution; The prepolymer solution is photocured on the surface of the encapsulation layer (14) to obtain the adhesive layer (15); the adhesive layer (15) is located on the surface of the encapsulation layer (14) between the two conductive hydrogel microneedle layers (13).

Citation Information

Cited By

  • Composite electrode for ear vagus nerve stimulation and preparation method and application thereof

    CN122251774A